SectorPharmaceutical
Established Date07/01/2014
Listing Date16/12/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees18
Fiscal Year Ends31/12
Security TypeCommon stock
Office address11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064
Business
IntroductionImmix Biopharma, Inc., was incorporated as a Delaware corporation on January 7, 2014. The Company is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (" CAR-T ") in light chain (AL) amyloidosis and autoimmune diseases. The Company's lead cell therapy drug candidate is CAR-T NXC-201, approved by the U.S. Food and Drug Administration (" FDA ") as an investigational new drug (" IND "), and is currently being evaluated in the Company's Phase 1 b/2 a NEXICART-1 (NCT04720313) clinical trial.
